![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Kala Sells Its Eye Disease Portfolio to Alcon
Kala Sells Its Eye Disease Portfolio to Alcon
Alcon is purchasing Kala Pharmaceuticals’ portfolio of eye disease drugs for an upfront payment of $60 million, plus potential milestone payments on future sales.
Under the agreement, Alcon will gain access to Kala’s Eysuvis (loteprednol etabonate) 0.25 percent ophthalmic suspension — indicated as a short-term treatment for dry-eye disease — and Inveltys (loteprednol etabonate) 1 percent ophthalmic suspension), which is for treatment of inflammation and pain following ocular surgery.
The agreement also includes collaborative development of Kala’s investigational drug, KPI-012, as a treatment for patients with persistent corneal epithelial defect, a severe eye disease involving a nonhealing corneal defect.
Upcoming Events
-
11Jul
-
18Jul
-
21Oct